propylene glycol has been researched along with Multiple Myeloma in 2 studies
Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Autologous stem cell transplantation (ASCT) after high-dose melphalan conditioning is considered a standard of care procedure for patients with multiple myeloma (MM)." | 9.20 | A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. ( Aljitawi, OS; Allen, LF; Arce-Lara, C; Bhat, G; Callander, N; Hari, P; Nath, R; Stockerl-Goldstein, K, 2015) |
| "Autologous stem cell transplantation (ASCT) after high-dose melphalan conditioning is considered a standard of care procedure for patients with multiple myeloma (MM)." | 5.20 | A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. ( Aljitawi, OS; Allen, LF; Arce-Lara, C; Bhat, G; Callander, N; Hari, P; Nath, R; Stockerl-Goldstein, K, 2015) |
| "For multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard of care with high-dose melphalan for transplant candidates." | 3.91 | Evaluating the adverse effects of melphalan formulations. ( Glotzbecker, B; Laubach, J; McDonnell, AM; Ni, J; Soiffer, R; Xiang, E, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xiang, E | 1 |
| Ni, J | 1 |
| Glotzbecker, B | 1 |
| Laubach, J | 1 |
| Soiffer, R | 1 |
| McDonnell, AM | 1 |
| Hari, P | 1 |
| Aljitawi, OS | 1 |
| Arce-Lara, C | 1 |
| Nath, R | 1 |
| Callander, N | 1 |
| Bhat, G | 1 |
| Allen, LF | 1 |
| Stockerl-Goldstein, K | 1 |
1 trial available for propylene glycol and Multiple Myeloma
| Article | Year |
|---|---|
A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Topics: Adult; Aged; Cyclodextrins; Drug Administration Schedule; Female; Graft Survival; Hematopoietic Stem | 2015 |
1 other study available for propylene glycol and Multiple Myeloma
| Article | Year |
|---|---|
Evaluating the adverse effects of melphalan formulations.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Drug Compounding; Drug-Related Side | 2019 |